Skip to main content

Kiora Pharmaceuticals Inc

KPRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001372514

No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.

Other share classesKPHMW

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +4 vs. previous quarter
22
13F valueReported value at the end of Q2 2026
$2.91M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding KPRX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding KPRX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Kiora Pharmaceuticals Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 12, 2024 (view filing)Sep 111 dayStengone Carmine N.DirectorPPurchase+1.25K$3.68+$4.60KNew position1.25K after
Sep 11, 2024 (view filing)Sep 101 dayShapiro AronDirectorPPurchase+3.00K$3.60+$10.8KNew position3.00K after
Aug 20, 2024 (view filing)Aug 191 dayWalters-Hoffert LisaDirectorPPurchase+1.25K$3.86+$4.83KNew position1.25K after
Aug 19, 2024 (view filing)Aug 19Same dayTyle PraveenDirectorPPurchase+5.00K$3.96+$19.8K+35,714.3%5.01K after
Aug 15, 2024 (view filing)Aug 141 dayTosca MelissaCFOPPurchase+2.00K$3.21+$6.42K+17.2%13.6K after
Jun 14, 2024 (view filing)Jun 14Same dayTosca MelissaEVP FinancePPurchase+100$5.25+$525+2.6%3.98K after
Jun 14, 2024 (view filing)Jun 14Same dayDaniels Eric JosephChief Development OfficerPPurchase+1.43K$5.29+$7.57K+14.6%11.2K after
Jun 13, 2024 (view filing)Jun 13Same dayParsons ErinDirectorPPurchase+5.26K$4.88+$25.7KNew position5.26K after
Jun 13, 2024 (view filing)Jun 13Same dayStrem Brian M.President and CEOPPurchase+3.00K$5.00+$15.0K+26.0%14.5K after
Nov 22, 2021 (view filing)Nov 184 daysStrem Brian M.President and CEOPPurchase+17.9K$1.41+$25.2K+187.6%27.4K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Kiora Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.

See all 22 holders
Institutions holding KPRX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Perceptive Advisors LLC438,471$1.15M0.02%+438,471New
ADAR1 Capital Management, LLC167,941$441.7K0.02%00.0%Unchanged
Citadel Advisors LLC116,011$305.1K0.00%+66,478+134.2%Added
Two Sigma Investments, LP88,792$233.5K0.00%+88,792New
Millennium Management LLC74,202$195.2K0.00%+74,202New
HRT Financial LP58,612$154.0K0.00%+58,612New
Renaissance Technologies LLC29,824$78.4K0.00%+29,824New
Geode Capital Management, LLC26,717$70.3K0.00%−21,133−44.2%Reduced
Vanguard Capital Management LLC19,861$52.2K0.00%00.0%Unchanged
Scientech Research LLC18,746$49.3K0.04%+18,746New